Introduction (1996)

Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus: The Fifth Regenstrief Conference1 January 1996IntroductionCharles M. Clark Jr., MD and Frank Vinicor, MDCharles M. Clark Jr., MDFrom the Regenstrief Institute, Richard L. Roudebush Veterans Affairs Medical Center, Indiana University School of Medicine, Indianapolis, Indiana; and the Centers for Disease Control and Prevention, Atlanta, Georgia.Search for more papers by this author and Frank Vinicor, MDFrom the Regenstrief Institute, Richard L. Roudebush Veterans Affairs Medical Center, Indiana University School of Medicine, Indianapolis, Indiana; and the Centers for Disease Control and Prevention, Atlanta, Georgia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Regenstrief Institute for Health Care“Sam” Regenstrief was recognized nationally as an authority on industrial production techniques. He contended that innovation and new technology as applied to medical and health system problems would provide better health care for more people at less cost. Sam joined forces with a nationally recognized authority in the health field, John B. Hickam, MD, then Chairman of the Department of Medicine at Indiana University School of Medicine, and the Regenstrief Foundation and Regenstrief Institute for Health Care were formed in 1969.The Fifth Regenstrief ConferenceThe Regenstrief Foundation directors established the Regenstrief Conferences in ...References 1. “The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.” Google Scholar 2. Pollett RJ, EI-Kebbi IM. The applicability and implications of the DCCT to NIDDM. Diabetes Reviews. 1994;2:413-27. Google Scholar 3. Nathan DM. Inferences and implications. Do results from the Diabetes Control and Complications Trial apply in NIDDM? Diabetes Care. 1995;18:251-7. CrossrefMedlineGoogle Scholar 4. Davidson MB. Why the DCCT applies to NIDDM patients. Clinical Diabetes. 1994; Nov/Dec:141-4. Google Scholar 5. Fletcher RH, Fletcher SW, Wagner EH, eds. Clinical Epidemiology: The Essentials. Second ed. Baltimore: Williams and Wilkins; 1988:172-87. Google Scholar 6. Vinicor F. Barriers to the translation of the Diabetes Control and Complications Trial. Diabetes Reviews. 1994;2:371-83. Google Scholar 7. Herman WH, Dashbach EJ, Songer TJ, Thompson DE, Crofford OB. Assessing the impact of intensive insulin therapy on the health care system. Diabetes Reviews. 1994;2:384-8. Google Scholar 8. Brown EY, Viscoli CM, Horwitz RI. Preventive health strategies and the policy makers' paradox. Ann Intern Med. 1992;116:593-7. LinkGoogle Scholar 9. “National Cholesterol Education Program (U.S.). Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Bethesda, Maryland: U.S. Department of Health and Human Services; 1990. NIH publication no. 90-3046.” Google Scholar 10. Pfeffer MA. ACE inhibition in acute myocardial infarction [Editorial]. N Engl J Med. 1995;332:118-20. CrossrefMedlineGoogle Scholar 11. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetologia. 1994;37:945-7. CrossrefMedlineGoogle Scholar 12. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia. 1994;37:948-52. CrossrefMedlineGoogle Scholar 13. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia. 1994;37:953-5. CrossrefMedlineGoogle Scholar 14. Stern MP. The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia. 1994;37:956-8. CrossrefMedlineGoogle Scholar 15. Abraira C, Colwell JA, Nuttall FQ, Swain CT, Nagel NJ, Comstock JP, et al . Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM). Diabetes Care. 1995;18:1113-23. CrossrefMedlineGoogle Scholar 16. Marrero DG. Current effectiveness of diabetes health care in the U.S. How far from the ideal? Diabetes Reviews. 1994;2:292-309. Google Scholar 17. Hiss RG, Anderson RM, Hess GE, Stepien CJ, Davis WK. Community diabetes care. A 10-year perspective. Diabetes Care. 1994;17:1124-34. CrossrefMedlineGoogle Scholar 18. Martin TL, Selby JV, Zhang D. Physician and patient prevention practices in NIDDM in a large urban managed-care organization. Diabetes Care. 1995;18:1124-32. CrossrefMedlineGoogle Scholar 19. Kenny SJ, Smith PJ, Goldschmid MG, Newman JM, Herman WH. Survey of physician practice behaviors related to diabetes mellitus in the U.S. Physician adherence to consensus recommendations. Diabetes Care. 1993;16:1507-10. CrossrefMedlineGoogle Scholar 20. Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995;332:1210-7. CrossrefMedlineGoogle Scholar 21. Lasker RD. The Diabetes Control and Complications Trial. Putting prevention into practice under health care reform. Diabetes Review. 1994;2:350-8. Google Scholar Author, Article, and Disclosure InformationAuthors: Charles M. Clark Jr., MD; Frank Vinicor, MDAffiliations: From the Regenstrief Institute, Richard L. Roudebush Veterans Affairs Medical Center, Indiana University School of Medicine, Indianapolis, Indiana; and the Centers for Disease Control and Prevention, Atlanta, Georgia.Grant Support: In part, by the Diabetes Research and Training Center, National Institutes of Health (PHS P60DK20542), the Regenstrief Institute, and the Veterans Affairs Research Service.Corresponding Author: Charles M. Clark Jr., MD, Regenstrief Institute, 1001 W. 10th Street, Indianapolis, IN 46202.Current Author Addresses: Dr. Clark: Regenstrief Institute, 1001 W. 10th Street, Indianapolis, IN 46202. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUse of glycated hemoglobin (HbA1C) and impaired glucose tolerance in the screening of undiagnosed diabetes in the Malaysian populationEffect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivityManaging and treating risk and uncertainty for health: a case study of diabetes among First Nation’s people in Ontario, CanadaAging, Comorbidity, and Reduced Rates of Drug Treatment for Diabetes MellitusDIABETES MELLITUS IN OLDER PERSONSLong term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical officeCost drivers in diabetes care: the problems they present and potential solutionsNonlipoprotein risk factors for coronary heart disease: Evaluation and management 1 January 1996Volume 124, Issue 1_Part_2Page: 81-85KeywordsCardiovascular diseasesDiabetes mellitusGlucoseHealth careHemoglobinInsulinInsulin resistanceInsulin-like growth factorsMedical risk factorsType 2 diabetes ePublished: 15 August 2000 Issue Published: 1 January 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...